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Results Data are reported from 20 patients. Fifteen 
patients (75 %) received all four doses of ipilimumab dur-
ing induction. Twelve patients (60 %) had at least one drug-
related adverse event (AE), and no patients discontinued 
due to a drug-related AE. There were no deaths related to 
study drug. The most common drug-related AEs were rash 
(n = 7), pyrexia (n = 3), increased aspartate aminotrans-
ferase (AST; n = 3), and increased alanine aminotrans-
ferase (ALT; n = 3). Twelve patients (60 %) reported 
immune-related AEs (irAEs); most frequent were skin 
(n = 9) and liver (n = 3) disorders. Grade 3 irAEs were 
ALT and AST elevation (n = 2) and diabetes mellitus 
(n = 1). Two patients had a partial response and two had 
stable disease, yielding a 20 % disease control rate. Median 
overall survival and progression-free survival were 8.71 
and 2.74 months, respectively.
Conclusion Ipilimumab 3 mg/kg had a manageable AE 
profile in this Japanese patient population with clinical out-
comes similar to that in Caucasian patients.
ClinicalTrials.gov identifier NCT01990859.
Keywords Ipilimumab · Immune-checkpoint inhibitor · 
Melanoma · Phase II study · Japanese patients
Introduction
Ipilimumab is a fully human IgG1 monoclonal antibody 
that blocks cytotoxic T-lymphocyte-associated antigen-4 
(CTLA-4), a key negative regulator of endogenous T cell-
mediated immune responses. Blockade of CTLA-4 has 
been shown to result in effector T cell activation, prolifera-
tion, and infiltration into tumors, as well as functional sup-
pression and depletion of regulatory T cells, which enhance 
antitumor immunity, resulting in tumor cell death [1–7]. 
Abstract 
Purpose Ipilimumab is designed to block cytotoxic 
T-lymphocyte antigen-4 to augment antitumor T cell 
responses. In studies of predominantly Caucasian patients 
with advanced melanoma, ipilimumab was associated with 
durable response, long-term survival benefit, and a manage-
able safety profile. This phase II study assessed the safety 
of ipilimumab in Japanese patients with unresectable stage 
III or IV melanoma.
Methods Patients received ipilimumab 3 mg/kg every 
3 weeks for four doses. The database lock for the original 
analysis was in August 2014. Overall survival, progression-
free survival, and data on deaths were based on an updated, 
follow-up analysis (database lock April 2015).
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Ipilimumab has been approved at a dose of 3 mg/kg by reg-
ulatory agencies in the USA and over 40 other countries for 
the treatment of advanced (unresectable or metastatic) mel-
anoma [7]. Approval was based upon a significant overall 
survival (OS) benefit demonstrated in two phase III stud-
ies [8, 9]. A 3-year survival rate of 22 % was observed in 
a pooled analysis of 1861 ipilimumab-treated patients with 
advanced melanoma from ten prospective clinical trials and 
two retrospective studies. The analysis showed a plateau in 
the survival curve beginning at approximately 3 years, with 
follow-up to 10 years in some patients [10].
In one phase III study, ipilimumab significantly 
improved OS in previously treated patients with advanced 
melanoma compared with a melanoma glycoprotein 100 
vaccine [8]. Similarly, in a phase III study in treatment-
naïve patients with advanced melanoma, ipilimumab at 
10 mg/kg in combination with dacarbazine significantly 
increased OS compared with dacarbazine alone [9]. Most 
adverse events (AEs) experienced with ipilimumab are 
inflammatory in nature and may reflect ipilimumab’s 
immune-based mechanism of action [8, 9, 11–13]. These 
immune-related AEs (irAEs) are generally manageable 
using product-specific treatment guidelines, which recom-
mend appropriate monitoring and corticosteroid treatment, 
and, if necessary, treatment interruption or discontinuation 
[11, 13–15].
Data from a phase I study of ipilimumab plus chemo-
therapy in Japanese patients with advanced non-small 
cell lung cancer showed that the efficacy and safety of 
ipilimumab were similar to those observed in studies of 
non-Japanese patients [16]. The primary objective of the 
current phase II study was to evaluate the safety of ipili-




Japanese patients who were 20 years of age or older were 
eligible for enrollment if they had histologically or cyto-
logically confirmed diagnosis of malignant melanoma, 
untreated or previously treated, stage III (unresectable) 
or stage IV melanoma. Other inclusion criteria included 
measurable/evaluable disease per modified World Health 
Organization (mWHO) criteria within 28 days of first dose 
of study drug; a life expectancy of at least 16 weeks; an 
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0 or 1; adequate hematologic, renal, and 
hepatic function; and negative screening tests for human 
immunodeficiency virus, hepatitis B, and hepatitis C 
and human T-lymphotropic virus type 1. Prior adjuvant 
melanoma therapy was permitted. Key exclusion crite-
ria included primary ocular or mucosal melanoma; active 
brain metastases with symptoms or requiring corticosteroid 
treatment (patients with stable, asymptomatic, controlled 
brain metastases were permitted if corticosteroids were not 
required for management); a history of, or current, autoim-
mune diseases; and prior anticancer therapy <4 weeks prior 
to first study treatment.
Study oversight
This study was sponsored by Bristol-Myers K.K. The study 
protocol was approved by the Institutional Review Board at 
each study institute, and research was conducted in accord-
ance with the standards specified by Article 14, Paragraph 
3, and Article 80-2 of the Pharmaceutical Affairs Law, 
and Good Clinical Practice, as defined by the Ministerial 
Ordinance Concerning the Standards for the Implementa-
tion of Clinical Studies on Pharmaceutical Products and 
concerning notifications, and in accordance with ethical 
principles underlying the Declaration of Helsinki. All study 
participants provided written informed consent prior to 
enrollment.
Study design and treatment
This was a single-arm, open-label study of ipilimumab 
monotherapy 3 mg/kg in untreated or previously treated 
Japanese patients with unresectable or metastatic mela-
noma (ClinicalTrials.gov, NCT01990859) (Fig. 1). Patients 
received four doses of ipilimumab 3 mg/kg intravenously 
every 3 weeks for a total of 12 weeks. Patients with disease 
progression, intolerable toxicity, or who discontinued study 
treatment in the induction phase, entered a follow-up phase 
and were followed for safety and survival for at least 1 year 
after the last patient’s first treatment. The planned study 
sample size was approximately 18 treated patients.
Study endpoints and assessments
The primary objective of this study was to assess the safety 
of ipilimumab monotherapy in Japanese patients with 
advanced melanoma. To assess safety, AEs were graded 
according the National Cancer Institute Common Termi-
nology Criteria for Adverse Events (CTCAE), version 3.0. 
irAEs were also summarized. Guidelines for the manage-
ment of AEs were provided by the sponsor (Supplemental 
Fig. 1) and have been published previously [11].
The secondary objective was to explore the antitumor 
activity [best overall response rate (BORR): complete 
response (CR) plus partial response (PR)] of ipilimumab 
monotherapy using mWHO criteria. Tumor assessments 
were performed at screening; weeks 12, 18, and 24; and 
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every 12 weeks thereafter. Determination of a response 
required confirmation with a subsequent scan at least 
4 weeks later.
Exploratory objectives included the assessment of dis-
ease control rate [DCR; CR plus PR plus stable disease 
(SD) assessed using mWHO criteria], OS, progression-free 
survival (PFS), and antidrug antibody (ADA) response to 
ipilimumab. Blood samples for assessment of ADAs were 
drawn before the ipilimumab infusion at weeks 1, 4, 7, and 
10 and at the end of treatment. Samples were analyzed at 
an external laboratory (Pharmaceutical Product Develop-
ment, LLC, Richmond, Virginia, USA).
Safety and efficacy were evaluated for all treated 
patients. The original database lock for safety and efficacy 
outcomes was in August 2014. These analyses were based 
on patients with at least 90 days of follow-up after the last 
dose of drug. OS, PFS and data on deaths are based on a 
follow-up analysis (database lock April 2015) 1 year after 
the last patient received the last dose of ipilimumab. BORR 
and DCR were calculated along with corresponding two-
sided 95 % confidence intervals (CIs). OS and PFS were 
calculated using Kaplan–Meier estimates, with medians 
and corresponding two-sided 95 % CIs reported.
Results
Patients and treatment
A total of 26 patients were enrolled into this study at 
six centers in Japan between December 2013 and Janu-
ary 2014; 20 patients were treated with ipilimumab, of 
whom 16 (80 %) had received prior anticancer therapy for 
advanced disease and 4 (20 %) were previously untreated. 
Six patients were enrolled, but not treated (five no longer 
met study criteria, and one withdrew consent). Patient 
demographics are shown in Table 1. At study entry, the 
majority had M1c disease (70 %), were ECOG perfor-
mance status 0 (70 %), and had elevated lactate dehydro-
genase (LDH) levels (60 %). Treated patients received 
a median of four cycles of ipilimumab, with 15 patients 
(75 %) receiving all four doses.
Safety
Safety data are summarized in Table 2. All patients reported 
at least one AE, and nine patients (45 %) had AEs of grade 
3/4 in severity. Twelve patients (60 %) had drug-related 
AEs, of which 3 (15 %) were grade 3 in severity [increased 
alanine aminotransferase (ALT), increased aspartate ami-
notransferase (AST), and diabetes mellitus]; there were 
no grade 4 drug-related AEs. The most frequently reported 
drug-related AE was rash. Eleven patients reported a seri-
ous AE (SAE); the events were considered drug-related in 
three patients (grade 3 ALT/grade 2 AST increase/grade 2 
C-reactive protein increase in one patient, grade 2 AST/
ALT increase in one patient, and grade 3 diabetes mellitus 
Fig. 1  Study design. BL base-
line, D day, IPI ipilimumab, PD 
progressive disease, q3wk every 
3 weeks, wk week. aPatients 
with PD, intolerability toxicity 
or who discontinued study treat-
ment during induction entered 
the follow-up phase and were 
followed for safety and survival 
for ≥1 year after the last 
patient’s first treatment
12 wk 12 wk
D1 D22 D43 D64




wk 12 wk 18 wk 24
Table 1  Patient demographics
ECOG Eastern Cooperative Oncology Group, LDH lactate dehydro-
genase
Characteristic Treated patients (N = 20)
Gender, male [n (%)] 10 (50)
Race, Japanese [n (%)] 20 (100)
Age, years [median (range)] 62.5 (29–76)
M stage at study entry [n (%)]
 M0 1 (5)
 M1a 1 (5)
 M1b 4 (20)
 M1c 14 (70)
ECOG performance status [n (%)]
 0 14 (70)
 1 6 (30)
Baseline LDH [n (%)]
 Normal 8 (40)
 Elevated 12 (60)
Prior systemic anticancer therapy [n (%)]
 Yes 16 (80)
 No 4 (20)
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in one patient). No patient discontinued the study due to 
toxicity related to study drug.
Twelve patients (60 %) had an irAE; the most frequently 
reported occurred in the skin and liver (Table 3). Other 
irAEs were gastrointestinal disorders, immune system dis-
orders, or metabolism and nutrition disorders. Most irAEs 
were grade 1/2 in severity. Three patients had a grade 3 
irAE: ALT elevation (n = 1), AST elevation (n = 1), and 
diabetes mellitus (n = 1). There were no grade 4 irAEs and 
no gastrointestinal perforations or neurological irAEs. The 
irAEs reported as SAEs were elevations in ALT (grade 2) 
and AST (grade 2) in one patient, elevations in ALT (grade 
Table 2  Ipilimumab safety data 
summary
AE adverse event, ALT alanine aminotransferase, AST aspartate aminotransferase
a AEs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse 
Events, version 3.0
b According to the most recent version of the Medical Dictionary for Regulatory Activities
Treated patients (N = 20)
Any grade Grade 3 or 4a
AEs [n (%)]
 Any AE 20 (100) 9 (45)
 Drug-related serious AEs 3 (15) 2 (10)
 Treatment-related AEs 12 (60) 3 (15)
Any grade occurring in ≥ 2 patients Grade 3
Treatment-related AEsa,b
 Rash 7 (35) 0 (0)
 Pruritus 2 (10) 0 (0)
 Pyrexia 3 (15) 0 (0)
 ALT increased 3 (15) 1 (5)
 AST increased 3 (15) 1 (5)
 Decreased appetite 2 (10) 0 (0)
 Diarrhea 2 (10) 0 (0)
 Diabetes mellitus – 1 (5)
Table 3  irAEs occurring in 
patients receiving ipilimumaba,b
a Patients may have had more than one event
b No grade 4 or 5 events were reported
ALT alanine aminotransferase, AST aspartate aminotransferase, irAE immune-related adverse event, Med-
DRA Medical Dictionary for Regulatory Activities
MedDRA system organ class preferred term [n (%)] Grade 1 Grade 2 Grade 3 Any grade
Any irAE 5 (25) 4 (20) 3 (15) 12 (60)
Skin and subcutaneous tissue disorders 5 (25) 4 (20) 0 (0) 9 (45)
 Rash 4 (20) 3 (15) 0 (0) 7 (35)
 Pruritus 1 (5) 1 (5) 0 (0) 2 (10)
 Alopecia 1 (5) 0 (0) 0 (0) 1 (5)
Investigations 1 (5) 0 (0) 2 (10) 3 (15)
 ALT increased 1 (5) 1 (5) 1 (5) 3 (15)
 AST increased 1 (5) 1 (5) 1 (5) 3 (15)
 Blood bilirubin increased 0 (0) 1 (5) 0 (0) 1 (5)
Gastrointestinal disorders 1 (5) 1 (5) 0 (0) 2 (10)
 Diarrhea 1 (5) 1 (5) 0 (0) 2 (10)
Immune system disorders 1 (5) 0 (0) 0 (0) 1 (5)
 Hypersensitivity 1 (5) 0 (0) 0 (0) 1 (5)
Metabolism and nutrition disorders 0 (0) 0 (0) 1 (5) 1 (5)
 Diabetes mellitus 0 (0) 0 (0) 1 (5) 1 (5)
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3) and AST (grade 2) in one patient, and diabetes mellitus 
(grade 3) in one patient.
The time to onset from first dose of ipilimumab for 
grade 2 or higher on-study irAEs was 1.1 weeks (grade 2 
hepatic irAE) to 13.6 weeks (grade 3 diabetes). For those 
events that resolved, the time to resolution ranged from 
0.6 weeks (grade 3 hepatic irAE) to 14.0 weeks (grade 2 
skin irAE). Eleven out of the 12 patients who had on-study 
irAEs received steroids for irAE management. All grade 2 
or higher on-study irAEs resolved to grade 1 or less fol-
lowing administration of steroids or symptomatic therapies, 
except for the grade 3 diabetes event. The grade 3 diabetes 
mellitus irAE remained unresolved at the time of reporting, 
and the patient was receiving insulin therapy and other anti-
diabetic medications.
Adverse events that occurred more than 90 days after 
the last dose of ipilimumab included 2 endocrine irAEs 
[grade 1 hypothyroidism and grade 2 hypopituitarism (also 
reported as an SAE)] and 1 skin irAE (grade 1 vitiligo). 
There were 13 deaths during the study, all due to disease 
progression (five deaths occurred within 90 days of the last 
dose of study drug and eight occurred more than 90 days 
after the last dose of study drug).
Antitumor activity
At 12 weeks after the last patient’s first treatment, four 
patients demonstrated antitumor activity (Table 4). Two 
patients (10 %) (1 pretreated, 1 untreated) had PR, and 
two patients (10 %) (both previously treated) had SD. 
The remaining patients had either progressive disease [13 
(65 %)] or were not evaluable [3 (15 %)] due to death 
before week 12. Disease control rate was 20 % (95 % CI 
5.7–43.7), and BORR was 10 % (95 % CI 1.2–31.7). The 
median OS was 8.71 months (95 % CI 3.71–not reached), 
and the median PFS was 2.74 months (95 % CI 1.25–2.83) 
(Fig. 2).
Pharmacokinetics
The study also investigated serum concentrations of ipili-
mumab relative to time of dosing. Results in Japanese 
patients were generally similar to those previously reported 
in predominantly Caucasian populations (data not shown).
Immunogenicity data
Three samples from two patients were confirmed positive 
for ADAs. Both patients had received all four doses of ipili-
mumab without dose delay and neither had any peri-infu-
sional hypersensitivity or anaphylactic reactions. One of 
the ADA-positive patients had SD, and the other had pro-
gressive disease. None of the three samples tested devel-
oped neutralizing antibodies.
Discussion
The findings from this study showed that the immune-
checkpoint inhibitor ipilimumab, administered at a dose 
of 3 mg/kg every 3 weeks for four doses, had a manage-
able safety profile with evidence of antitumor activity in 
this group of Japanese patients with advanced melanoma. 
The safety profile was consistent with the previous expe-
rience with 3 mg/kg ipilimumab in global clinical studies 
involving primarily Caucasian patients [8, 9]. As reported 
previously, the most common treatment-related AEs with 
ipilimumab therapy were immune-related, presumably 
reflecting the drug’s immune-based mechanism of action, 
affecting the skin, liver, gastrointestinal tract, and endo-
crine system [12]. Most of the irAEs observed in the cur-
rent study were mild-to-moderate in severity, and no grade 
4 irAEs were reported. The tolerability of ipilimumab in 
the current study is supported by the observation that no 
patient withdrew from the study due to a drug-related AE. 
Importantly, no new safety signals were observed in this 
group of Japanese patients compared with those seen in 
earlier studies across the world [8, 9], and there were no 
study-drug-related deaths.
Extensive global experience with ipilimumab enabled 
the development of effective treatment guidelines for the 
management of irAEs (Supplementary Fig. 1; [11]). The 
guidelines emphasize early diagnosis and appropriate 
treatment as essential to minimize severe and potentially 
life-threatening complications [11, 13]. These guidelines 
were used as a basis for the development of the protocol 
for the current study, and following these guidelines may 
have contributed to the absence of the grade 4 irAEs. Ipili-
mumab treatment guidelines recommend symptomatic 
treatment for mild irAEs with delay or omission of a dose 
and intense monitoring for more severe events. In the case 
Table 4  Best overall response and disease control rates
CI confidence interval
a Number of patients with CR or PR/number of treated patients
b Number of patients with CR, PR, or SD/number of treated patients
Best overall response Treated patients (N = 20)
Complete response (CR) [n (%)] 0 (0)
Partial response (PR) [n (%)] 2 (10.0)
Stable disease (SD) [n (%)] 2 (10.0)
Progressive disease [n (%)] 13 (65.0)
Not evaluable [n (%)] 3 (15.0)
Best overall response rate [n (% [95 % 
CI])a]
2 (10 [1.2–31.7])
Disease control rate [n (% [95 % CI])b] 4 (20 [5.7–43.7])
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of persistent or high-grade irAEs, ipilimumab should be 
discontinued and patients should be treated with high-dose 
systemic corticosteroids (with slow taper to reduce the risk 
of relapse). Patients who are refractory to steroid treatment 
may require alternative immunosuppressive therapies, such 
as infliximab (antitumor necrosis alpha treatment). Clini-
cal studies have shown that most irAEs are reversible when 
these guidelines are followed [11, 13].
In the current study, most of the patients with on-study 
irAEs received steroids. All irAEs except the grade 3 dia-
betes mellitus resolved to grade 1 or less, including the two 
patients with grade 3 liver irAEs. Both of these patients 
resumed ipilimumab treatment and completed the full 
four doses of ipilimumab without recurrence of the liver 
irAE. The grade 3 diabetes was ongoing but manageable 
with insulin at the time of reporting. The patient had no 
medical history of diabetes, suggesting it was caused by an 
immune-mediated mechanism. However, previous global 
experience with ipilimumab suggests diabetes and hyper-
glycemia are uncommon irAEs [11]. In the current study, 
most irAEs resolved within 1 to 14 weeks; this is consistent 
with previous global experience where the time to resolu-
tion for the most common irAEs typically ranged from 4 to 
9 weeks depending on the organ system involved [13].
The majority of irAEs in the current study occurred 
during ipilimumab treatment or within 90 days of the 
last dose. However, two endocrine irAEs (grade 1 hypo-
thyroidism and grade 2 hypopituitarism) and one skin 
irAE (grade 1 vitiligo) were reported more than 90 days 
after the last dose. Grade 2 hypopituitarism was managed 
with steroid therapy, and at the time of database lock, the 
event remained unresolved as treatment with hormone 
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Fig. 2  Kaplan–Meier curves for overall survival (a) and progression-free survival (b)
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replacement therapy continued. No treatment was required 
for grade 1 hypothyroidism and vitiligo. These findings are 
consistent with previous reports that ipilimumab may cause 
late-onset irAEs, including endocrine-related events [17]. 
For example, in the international phase III trial MDX010-
20, one patient (4.2 %) who received ipilimumab plus pla-
cebo experienced late-onset (>70 days after last dose) grade 
1 vitiligo and grade 2 hypothyroidism [17]. Patients treated 
with ipilimumab plus gp100 in MDX010-20 also reported 
late-onset AEs including grade 1 vitiligo (n = 3, 5.6 %), 
grade 2 hypogonadism and reduced serum testosterone 
(n = 1, 1.9 %), and grade 1 diarrhea, grade 2 proctitis, and 
grade 3 colitis (n = 1, 1.9 %) [17]. These data emphasize 
the importance of ongoing patient follow-up and vigilance 
for irAEs after treatment has stopped.
Assessment of antitumor activity with ipilimumab was 
a secondary objective in this study. The BORR of 10 % 
and DCR of 20 % are similar to those reported in the 
phase III study with ipilimumab 3 mg/kg in previously 
treated, primarily Caucasian patients [8]. Additionally, 
as reported in other studies, responses were observed in 
patients regardless of whether they had received prior 
therapies [8, 9]. Long-term follow-up of ipilimumab-
treated patients in global clinical studies has shown the 
potential of ipilimumab for durable long-term survival in 
approximately 20 % patients with advanced melanoma 
[10]. This durable survival benefit, despite relatively low 
response rates, is likely a result of ipilimumab’s immune-
mediated mechanism of action, with which it can take 
longer for a detectable antitumor response to occur com-
pared with cytotoxic agents. The kinetics of antitumor 
activity may also be different from other agents, mean-
ing that conventional response criteria (such as those of 
mWHO) may not fully capture the antitumor activity of 
ipilimumab [13].
Although ipilimumab is a fully human antibody, data 
suggest the potential for the induction of ADAs [18]. In 
the current study, two patients were positive for ADAs. 
However, because of the low number of positive samples 
throughout the study and the observed safety and activ-
ity profiles, particularly in the patients who were positive 
for ADAs (neither had a peri-infusional hypersensitiv-
ity or anaphylactic reaction, and one patient had SD), the 
development of ADAs after ipilimumab treatment is not 
expected to have a clinically relevant impact on safety or 
activity [18].
Antitumor activity has been demonstrated with 
another immune-checkpoint inhibitor, nivolumab, 
approved in Japan in 2014 for patients with unresectable 
or metastatic melanoma regardless of prior treatment. 
Nivolumab is a fully human IgG4 programmed death 1 
(PD-1) immune-checkpoint inhibitor with a different 
mechanism of action from that of ipilimumab [19]. In a 
phase III trial (CheckMate 037 [20]), 405 patients with 
advanced melanoma who had progressed after receiving 
ipilimumab, or ipilimumab and a BRAF inhibitor if they 
were BRAF V600 mutation-positive, were treated with 
nivolumab monotherapy or chemotherapy. Nivolumab 
treatment resulted in a confirmed objective response rate 
(ORR) of 32 % that was significantly higher than that 
in the chemotherapy group (11 %). Safety profiles with 
nivolumab were similar to those of previously untreated 
patients, suggesting that prior treatment with ipilimumab 
did not adversely affect patient safety. A phase II trial 
(CheckMate 069 [21]) of treatment-naïve patients dem-
onstrated that combination therapy with ipilimumab and 
nivolumab resulted in significantly improved ORR com-
pared with ipilimumab monotherapy (61 % compared 
with 11 %, respectively, in BRAF wild-type patients). 
A phase III study of combination treatment (Check-
Mate 067) reported an ORR of 44 % with nivolumab, 
58 % with nivolumab plus ipilimumab, and 19 % with 
ipilimumab alone [22]. Median PFS was 6.9, 11.5, and 
2.9 months, respectively [22].
In summary, findings from the current phase II study 
showed that ipilimumab monotherapy at 3 mg/kg had a 
manageable safety profile and produced antitumor activ-
ity in this Japanese patient population, regardless of 
whether the patient had received prior treatment. These 
findings are consistent with the known safety and activ-
ity profile of ipilimumab established in global clinical 
studies.
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